BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36915069)

  • 1. Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.
    Nguyen VC; Nguyen TH; Phan TH; Tran TT; Pham TTT; Ho TD; Nguyen HHT; Duong ML; Nguyen CM; Nguyen QB; Bach HT; Kim VV; Pham TA; Nguyen BT; Nguyen TNV; Huynh LAK; Tran VU; Tran TTT; Nguyen TD; Phu DTB; Phan BHH; Nguyen QT; Truong DK; Do TT; Nguyen HN; Phan MD; Giang H; Tran LS
    BMC Cancer; 2023 Mar; 23(1):233. PubMed ID: 36915069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma.
    Tao K; Bian Z; Zhang Q; Guo X; Yin C; Wang Y; Zhou K; Wan S; Shi M; Bao D; Yang C; Xing J
    EBioMedicine; 2020 Jun; 56():102811. PubMed ID: 32512514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
    Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
    Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
    Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
    Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA.
    Lin D; Luo R; Ye Z; Wei Q; Bae H; Juon HS; Hann HW; Posey J; Wang C
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102161. PubMed ID: 37307947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
    Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
    Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
    Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
    Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M
    Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
    Li X; Wang H; Li T; Wang L; Wu X; Liu J; Xu Y; Wei W
    Curr Probl Cancer; 2020 Apr; 44(2):100516. PubMed ID: 31836136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
    Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
    Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
    Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
    Fan ZH; Ren F
    Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1382-1386. PubMed ID: 36891725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
    Dhayat SA; Yang Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.